BLRX vs. IMMP, RANI, MGNX, FHTX, QURE, ACRV, AKBA, HOWL, NKTR, and ALDX
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Immutep (IMMP), Rani Therapeutics (RANI), MacroGenics (MGNX), Foghorn Therapeutics (FHTX), uniQure (QURE), Acrivon Therapeutics (ACRV), Akebia Therapeutics (AKBA), Werewolf Therapeutics (HOWL), Nektar Therapeutics (NKTR), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
Immutep has higher earnings, but lower revenue than BioLineRx.
Immutep presently has a consensus target price of $8.50, indicating a potential upside of 185.23%. BioLineRx has a consensus target price of $21.00, indicating a potential upside of 2,716.52%. Given Immutep's higher possible upside, analysts plainly believe BioLineRx is more favorable than Immutep.
BioLineRx's return on equity of 0.00% beat Immutep's return on equity.
BioLineRx received 194 more outperform votes than Immutep when rated by MarketBeat users. Likewise, 73.36% of users gave BioLineRx an outperform vote while only 72.43% of users gave Immutep an outperform vote.
2.3% of Immutep shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, BioLineRx had 12 more articles in the media than Immutep. MarketBeat recorded 16 mentions for BioLineRx and 4 mentions for Immutep. BioLineRx's average media sentiment score of 0.86 beat Immutep's score of 0.85 indicating that Immutep is being referred to more favorably in the media.
Immutep has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Summary
Immutep beats BioLineRx on 9 of the 14 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
